Delivering Revolutionary Cell/Gene Therapies to the Underserved, Creating More Accessibility
By David Jensen,
The California Stem Cell Report
| 04. 24. 2023
What good is a “miraculous” cure or a revolutionary therapy -- which is the goal of a $12 billion state of California enterprise -- if it is not accessible to patients?
That’s a question implicitly posed by a former member of the governing board of that enterprise, the California Institute for Regenerative Medicine (CIRM), more commonly known as the stem cell agency. And he had an answer to the question and a suggestion for the state program.
The remarks come from Jeff Sheehy, who served on the board for 16 years beginning in 2004, the year CIRM was created. He sent the California Stem Cell Report a note after the publication of an article about CIRM’s $80 million effort to create a public-private manufacturing network to overcome obstacles to the production of stem cell and related therapies.
Sheehy spoke to the lack of availability of advanced medical care in underserved areas of California, many of which are rural and remote from the centers where cell and genetic treatments can be done. He proposed that CIRM develop a “capacity... see more
Related Articles
By CGS Staff
| 05.15.2023
On May 4, the Center for Genetics and Society contributed invited remarks about heritable gene editing at a comment session hosted by the National Council on Disability (NCD), the US federal agency that advises government and the private sector on disability policy. Some 17 speakers, including representatives of disability and patient advocacy organizations, scholars, medical researchers, and genetic counselors, weighed in for three minutes each on the topic “Germline editing, fetal medicine, and their impact on people with disabilities.”
The...
By Rob Stein, NPR | 05.02.2023
When Chase Finazzo was just a few years old, his parents noticed Chase was pretty clumsy. But they didn't think it was anything serious.
"He would fall a lot. Not like a lot a lot. But he had trouble climbing...
By Sarojini Nadimpally, The BMJ | 05.03.2023
Challenges exist around heritable gene editing, its potential medical applications, ethical implications, and the need for regulatory mechanisms in the field. In March this year I spoke at the Third International Summit on Human Genome Editing, held in London, about...
By Editorial, Nature | 04.25.2023
